Novo Nordisk, semaglutide
Compounded semaglutide associated with at least 10 deaths, Novo Nordisk CEO warns
the chief executive of Ozempic maker Novo Nordisk warned Wednesday. “Honestly, I’m quite alarmed by what we see in the US now,” Novo Nordisk President and CEO Lars Fruergaard Jorgensen told CNN. “Patients who believe that they’re getting access ...
Novo Nordisk CEO warns of deaths linked to compounded semaglutide
The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of the active ingredient in those medications have now been linked to at least 100 hospitalizations and 10 deaths.
7don MSN
Novo Nordisk, the pharma giant behind Ozempic and Wegovy, has surprising love story origins. The founders, a married couple, ...
Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and ...
Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage ...
7don MSN
Novo Nordisk scientist Lotte Knudsen, whose research led to Ozempic and Wegovy, started her career developing laundry ...
Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...
Investopedia on MSN4d
Novo Nordisk Stock Slips as Sales Grow Less Than ExpectedAfter rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its ...
All doses of Novo Nordisk's weight loss injection Wegovy and diabetes drug Ozempic are now available in the U.S., according to an update on the FDA's drug shortage database. It is a sign that ...
Novo Nordisk on Wednesday nudged higher its profit outlook for the year as the drugmaker registered another quarter of strong sales of its weight-loss drugs. Novo Nordisk said its ...
Novo Nordisk (NVO) teased some new details about a potential Ozempic successor during a call with investors Tuesday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback